Automate Your Wheel Strategy on SPRY
With Tiblio's Option Bot, you can configure your own wheel strategy including SPRY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SPRY
- Rev/Share 0.9904
- Book/Share 2.335
- PB 7.6744
- Debt/Equity 0.0003
- CurrentRatio 11.0007
- ROIC -0.092
- MktCap 1759987712.0
- FreeCF/Share -0.2147
- PFCF -83.59
- PE -112.2841
- Debt/Assets 0.0002
- DivYield 0
- ROE -0.0694
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | SPRY | Scotiabank | -- | Sector Outperform | -- | $30 | March 7, 2025 |
| Initiation | SPRY | Oppenheimer | -- | Outperform | -- | $40 | Feb. 10, 2025 |
| Initiation | SPRY | Cantor Fitzgerald | -- | Overweight | -- | -- | Aug. 20, 2024 |
News
EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
Published: July 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
EUR neffy ( neffy ® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children ( > 30 kg) living with severe allergic reactions
Read More
ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Does ARS Pharmaceuticals, Inc. (SPRY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for ARS Pharmaceuticals, Inc. (SPRY) points to a 78.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing'
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
ARS Pharmaceuticals, Inc. (SPRY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Read More
ARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings Call Transcript
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Neutral
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Justin Chakma - CBO Richard Lowenthal - Co-Founder, President and CEO Eric Karas - CCO Kathleen Scott - CFO Conference Call Participants Ryan Deschner - Raymond James Josh Schimmer - Cantor Roanna Ruiz - Leerink Partners Lachlan Hanbury-Brown - William Blair Andreas Argyrides - Oppenheimer Louise Chen - Scotiabank Operator Good morning and welcome to ARS Pharmaceuticals' Conference Call. At this time, all participants are in listen-only mode.
Read More
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Neutral
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago.
Read More
ARS Pharmaceuticals Has A Blockbuster Candidate
Published: April 30, 2025 by: Seeking Alpha
Sentiment: Positive
ARS Pharmaceuticals has a recently launched needle-free epinephrine product for allergic reactions, neffy, and strong cash reserves. The company targets a ~$3B+ U.S. market, geographic expansion and intends to also address acute flares in chronic spontaneous urticaria. Financial projections include $500M peak U.S. sales, $500M outside the U.S., and $150M for chronic spontaneous urticaria, with profitability expected by 2027.
Read More
ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript
Published: March 20, 2025 by: Seeking Alpha
Sentiment: Neutral
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Justin Chakma - Chief Business Officer Richard Lowenthal - Co-Founder, President and CEO Eric Karas - Chief Commercial Office Kathleen Scott - CFO Conference Call Participants Ryan Deschner - Raymond James Alexa Deemer - Cantor Fitzgerald Louise Chen - Scotia Bank Roanna Ruiz - Leerink Partners Lachlan Hanbury-Brown - William Blair Julian Harrison - BTIG Operator Good day, and welcome to ARS Pharmaceuticals Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time all participants are in listen-only mode.
Read More
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
$7.3 million in total neffy ® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024
Read More
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
Published: March 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company to Host Conference Call on March 20 at 8:30 a.m. ET SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Thursday, March 20, 2025, at 8:30 a.m.
Read More
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Approximately five months after launch, the inclusion of neffy on these three additional formularies has expanded access to half of all patients and caregivers managing Type 1 allergic reactions, bringing the total number of formulary platforms covering neffy to 30
Read More
ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Oral presentation on an efficacy study conducted in Japanese patients comparing anaphylaxis symptoms during oral food challenge with neffy as the initial treatment compared to site historical data on intramuscular auto-injectors, antihistamines and inhalers; patients receiving neffy had lower symptom scores within 10 minutes, supporting neffy as a needle-free option for management of anaphylaxis neffy was shown to be in the safe and efficacious range for children four years or older who weigh more than 15 kilograms Findings in Chinese studies confirms U.S. data and bracketed pharmacokinetic (PK) and pharmacodynamic (PD) profiles, demonstrate neffy's comparable efficacy and safety under various …
Read More
About ARS Pharmaceuticals, Inc. (SPRY)
- IPO Date 2020-12-04
- Website https://ars-pharma.com
- Industry Biotechnology
- CEO Richard E. Lowenthal MSMSEL
- Employees 155